… monoclonal antibodies (mAbs) neutralizing SARS-CoV-2 … (NTD) of S protein from
SARS-CoV-2 convalescent donors and … of authentic SARS-CoV-2 and recombinant VSV/SARS-CoV-2 …

… –510 of the SARS-CoV S protein. Affinity measurements showed an affinity Kd of 34 nM
between monoclonal antibodies (mAbs) and soluble S 590 (residues 1–590 of the SARS-CoV S …

… antibodies have therapeutic potential. We have purified more than 1,000 memory B cells
specific to SARS-CoV-2 … Among these, 178 antibodies test positive for antigen binding, and the …

… Consistently, we also found that SARS-CoV-2 RBD-specific IgG antibodies were present in
… whether RBD-specific antibodies in patient serum can block the binding of SARS-CoV-2 RBD …

Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
remaining at risk of coronavirus disease 2019 (COVID-19). Monoclonal antibodies (mAbs) …

… of vaccinations and monoclonal antibodies. Our in vitro findings using authentic SARS-CoV-2 …
Since SARS-CoV-2 Omicron was resistant to casirivimab and imdevimab, genotyping of …

… activity against SARS-CoV. We solved the cryo-EM structure of 2–36 in complex with
SARS-CoV-2 or SARS-CoV spike, … Antibody 2–36 neutralized not only all current circulating …

… treated with neutralising monoclonal antibodies (mAbs)… antibodies targeting relatively
conserved regions, individually eg sotrovimab. Unprecedented genomic surveillance of SARS-CoV…

… What are the current roles for anti–SARS-CoV-2 monoclonal antibodies and how might they
be used in the future? At this time, anti–SARS-CoV-2 monoclonal antibodies are authorized …

… The emergence of SARS-CoV-2 antibody escape mutations highlights the urgent need for …
monoclonal antibody, 47D11, capable of cross-neutralizing SARS-CoV-2 and SARS-CoV and …